[Brexucabtagene autoleucel (acute lymphatic r/r B cell leukemia, from 26 years of age) - Assessment according to §35a SGB V (1), Sentence 11]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004287
German
Original Title:
Brexucabtagen-Autoleucel (akute lymphatische r/r B-Zell-Leukaemie, ab 26 Jahren)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g22-34.html
Year Published:
2022
URL for published report:
https://www.iqwig.de/download/g22-34_brexucabtagen-autoleucel_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Antineoplastic Agents, Immunological
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
- Antigens, CD19
Keywords
- Brexucabtagene Autoleucel
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.